Penalty Amount
$469,000,000
Colorado joined a 43-state-and-territory settlement resolving allegations that Sandoz and Fougera participated in a long-running conspiracy to inflate generic drug prices, reduce competition, and restrain trade. The companies agreed to pay approximately $469 million and implement reforms; the states are seeking court approval.
Sandoz agreed to pay approximately $469 million to settle the states’ claims and to implement reforms intended to ensure fair competition and compliance with antitrust laws. Eligible consumers may seek compensation for qualifying generic-drug purchases.
Review supplier, manufacturing, distribution, and customer agreements for provisions that could facilitate coordinated pricing or restrict competition, including exclusivity, pricing controls, information-sharing, market-allocation, and restrictions on competing products. Vendor and affiliate agreements should clearly allocate antitrust compliance obligations, extend those obligations to relevant affiliates and subcontractors, and provide audit, cooperation, and termination rights for suspected misconduct. This action concerns antitrust allegations rather than privacy practices, so it does not itself indicate a need to revise privacy, data-processing, or breach-notification clauses.
Entity
Sandoz Inc. and Fougera Pharmaceuticals Inc.
Industry
HealthcareOfficial Press Release
https://coag.gov/press-releases/colorado-slated-to-receive-2-1m-from-nationwide-settlement-with-sandoz-over-illegal-generic-drug-price-hikes-and-collusion/
10.1.26 Sandoz
https://coag.gov/app/uploads/2026/10/10.1.26-Sandoz.pdf
Colorado Attorney General Enforcement Page
https://coag.gov/
"with Sandoz Inc. and Fougera Pharmaceuticals Inc."
"Under the terms of this agreement, Sandoz will pay a total of approximately $469 million to settle the claims brought by the states."
"compliance with antitrust laws."
"engaged in a widespread, long-running conspiracy to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade"
$400.0M
New York Attorney General Letitia James and a coalition of 47 other attorneys general secured a $400 million settlement with Sandoz Inc. and Fougera Pharmaceuticals Inc. over an alleged scheme to coordinate generic drug prices and reduce competition. The settlement provides for consumer compensation and requires Sandoz to implement antitrust compliance reforms, including annual staff training and a Chief Compliance Officer.
$400.0M
Connecticut Attorney General William Tong announced a $400 million settlement with Sandoz Inc. and Fougera Pharmaceuticals Inc. resolving allegations that the generic drug manufacturers conspired to inflate prices, limit competition, and restrain trade. The settlement includes consumer restitution and injunctive reforms; court approval was being sought.
Colorado Attorney General Phil Weiser joined a multistate and local coalition challenging the EPA’s repeal of greenhouse gas limits for many coal- and gas-fired power plants. The coalition seeks to have the repeal struck down and the protections restored, and separately notified the EPA of its intent to sue over regulation of emissions from existing gas plants; no penalty or final court remedy is reported.
$35.0M
Colorado, the FTC, and a coalition of state attorneys general reached a settlement with Corteva over allegations that its post-patent loyalty program restricted distributors from selling competing generic pesticides. Corteva must end the challenged conduct and pay the states $35 million for fees and costs; the agreement is in effect for 10 years.
$2.3M
Colorado and a bipartisan coalition of attorneys general reached a $2,287,455 settlement with Laboratory Corporation of America over the 2019 data breach at its debt collector, American Medical Collection Agency. The settlement requires stronger vendor risk management and information security practices, with particular requirements for medical debt collectors.
Colorado Attorney General Phil Weiser joined a coalition of 12 attorneys general in settling a lawsuit against Paramount Skydance Corporation over its merger with Warner Bros. Discovery, which the states alleged would harm competition by lowering film output and raising prices. The settlement includes a five-year commitment to increase film output, a $1.5 billion investment in domestic production, a $47.5 million worker fund, and an independent monitor. This is an antitrust/competition enforcement action, not a privacy enforcement action, despite the extraction schema's privacy focus.